OncoReview https://www.journalsmededu.pl/index.php/OncoReview <p>The main area of <em>OncoReview’s </em>&nbsp;scientific mission is the emerging field of interdisciplinary oncology, with particular emphasis on cardio-oncology. Scientific papers published in the journal concern modern diagnostic and therapeutic methods used in this population of patients, as well as all adverse events related to anticancer treatment. Objective assessment of the benefits and risks of new oncological drugs is a unique benefit of the published works.&nbsp;<br><span lang="en-GB"><br></span><span lang="en-GB"><strong>e-ISSN: </strong>2450-6125&nbsp; <strong>&nbsp; &nbsp; &nbsp; DOI: </strong>10.24292/01.OR<br><br><strong>Indexed in:&nbsp;</strong></span><strong>SCOPUS</strong>: SJR 2019 = 0.125; SNIP 2019= 0.099<br><span lang="en-GB">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Polish Journals Master List:&nbsp;<strong>20 points</strong>&nbsp;<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Index Copernicus: 116.25&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Google Scholar<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Polish Medical Bibliography</span></p> <p>&nbsp;</p> en-US <p><strong>Copyright: © Medical Education sp. z o.o.</strong>&nbsp;This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (<a href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</a>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</p> <p><em>Address reprint requests to: Medical Education, Marcin Kuźma (<a href="mailto:marcin.kuzma@mededu.pl">marcin.kuzma@mededu.pl</a>)</em></p> marcin@journalsmededu.pl (Marcin Kuzma) m.maslowski@mededu.pl (Marcin Masłowski) Tue, 16 Feb 2021 00:00:00 +0100 OJS http://blogs.law.harvard.edu/tech/rss 60 Stereotactic management of arrhythmia – radiosurgery in treatment of ventricular tachycardia (SMART-VT) – clinical trial protocol and study rationale https://www.journalsmededu.pl/index.php/OncoReview/article/view/1147 <p>Patients with ventricular tachycardia are usually treated with antiarrhythmic drugs and ablation if the arrhythmia substrate is available for invasive treatment. Despite high efficiency of this treatment there is a significant group of patients who do not benefit from available treatment methods, either because they cannot be applied or do not allow for durable control of the disease. For that reason a novel treatment method, STereotactic Arrhythmia Radioablation (STAR) has been proposed and its safety and efficiency is extensively studied throughout the world. The method is based on irradiation of the arrhythmia substrate identified with electrophysiological examination with high-precision image-guided radiosurgical methods usually used for ablation of malignant tumors. Here we present the protocol of the first Polish study on STAR in patients with intractable ventricular tachycardia (STARVT, NCT04642963), designed to test the safety of the method. Secondary endpoints include measures of the treatment efficiency.</p> Marcin Miszczyk , Tomasz Jadczyk , Bartłomiej Tomasik , Tomasz Latusek , Jacek Bednarek , Radosław Kurzelowski , Krzysztof Gołba , Wojciech Wojakowski , Krystian Wita , Łukasz Dolla , Aleksandra Grządziel , Sławomir Blamek Copyright (c) 2021 Medical Education https://creativecommons.org/licenses/by-nc-nd/4.0/ https://www.journalsmededu.pl/index.php/OncoReview/article/view/1147 Sun, 14 Feb 2021 00:00:00 +0100 The oncological treatment and cardiotoxicity problem – the role of biomarkers https://www.journalsmededu.pl/index.php/OncoReview/article/view/1106 <p>Cancer and cardiovascular diseases are a leading causes of morbidity and mortality in developed countries. Cardiological complications of oncological treatment are a significant problem that can be manifested in both permanent and transient cardiac dysfunction including myocardial damage, left ventricular dysfunction, and heart failure, hypertension, ischemia, as well as arrhythmias or QT prolongation, which can be life-threatening. Early detection of cardiotoxicity due to cancer treatment is crucial in the prevention of adverse cardiovascular outcomes in this group of patients. In this review we try to summarize the role of biomarkers in the detection of cardiotoxicity due to cancer treatment.</p> Magdalena Dudek , Marta Kałużna-Oleksy , Jacek Migaj , Maciej Lesiak , Ewa Straburzyńska-Migaj Copyright (c) 2020 Medical Education https://creativecommons.org/licenses/by-nc-nd/4.0/ https://www.journalsmededu.pl/index.php/OncoReview/article/view/1106 Fri, 04 Dec 2020 00:00:00 +0100 Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer – diagnostic difficulties https://www.journalsmededu.pl/index.php/OncoReview/article/view/1143 <p>&nbsp;Cancer-related microangiopathic hemolytic anemia is rarely recognized as a paraneoplastic syndrome with a very poor prognosis in cancer patients. The treatment and prognosis are significantly different from that in other thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The case of described patient demonstrates the diagnostic difficulties in diagnosing the causes of hemolytic anemia in patient with breast cancer and appropriate treatment.</p> Kamila Skwierawska , Krzysztof Woźniak , Anna Waszczuk-Gajda , Joanna Drozd-Sokołowska , Piotr Kacprzyk , Marita Rachid Chehab , Piotr Boguradzki , Wiesław Wiktor Jędrzejczak , Grzegorz Władysław Basak Copyright (c) 2020 Medical Education http://creativecommons.org/licenses/by-nc-nd/4.0/ https://www.journalsmededu.pl/index.php/OncoReview/article/view/1143 Thu, 31 Dec 2020 00:00:00 +0100 Monoclonal gammopathy of renal significance – diagnostic and therapeutic problems https://www.journalsmededu.pl/index.php/OncoReview/article/view/1145 <p>The term <em>monoclonal gammopathy of renal significance</em> MGRS means a group of renal diseases resulting from the presence of the monoclonal protein produced by plasmatic cells or other clones of B cells. The patients with MGRS do not fulfill the diagnostics criteria both of multiple myeloma and other neoplasm originating from B cells. The involvement of different renal structures in the course of MGRS results the dysfunction of kidneys. The monoclonal protein may injure the glomerular structures (including vascular) as well as tubular structures (interstitial in more wide sense). The early diagnosis of MGRS is difficult and the late detection of the disease is connected with high risk of irreversible renal damage. Therefore, the multidisciplinary cooperation – including general practitioners, nephrologists, hematologists and nephro-pathologists – is particularly important for the diagnostics and treatment of MGRS cases. This new hemato-nephrological meta-disease entity is connected with relatively high morbidity and mortality as well as relapses in transplanted kidney. The decision of the treatment initiation against the toxic clone in MGRS cases results mainly from the nephrological reasons. The article presents current diagnostic and therapeutic possibilities that may be used in MGRS patients. The main purpose of this article was to present the current state of knowledge regarding the diagnostics and treatment of MGRS.</p> Grzegorz Kade , Sebastian Spaleniak , Janusz Hałka , Stefan Antosiewicz Copyright (c) 2021 Medical Education http://creativecommons.org/licenses/by-nc-nd/4.0/ https://www.journalsmededu.pl/index.php/OncoReview/article/view/1145 Thu, 04 Feb 2021 00:00:00 +0100 Cancer pain as a meaningful aspect of the oncological treatment https://www.journalsmededu.pl/index.php/OncoReview/article/view/1146 <p><strong>Introduction and objective</strong>: Pain is the most common and universal symptom among all patients with the oncological disease. Pain significantly reduces the quality of life, hinders decent functioning, and plays a significant role in the deterioration of the mental health of the patient and his close relatives. The study aimed to discuss the mainstreaming of effective pain treatment and to review various assessments and scales (including Brief Pain Inventory, Illness Perception Questionnaire and Numeric Rating Scale) concerning the psychological aspect of pain in selected neoplastic diseases.State of knowledge: We can distinguish various treatments for pain that can be divided into pharmacological and non-pharmacological methods. Latest studies revealed that pain treatment appears to be more and more meaningful. Various factors might influence pain perception and response to the applied treatment. Among all malignancies, special attention is paid to the pain issue in following cancers: colon cancer, gastric cancer, pancreatic cancer, ovarian cancer, breast cancer and lung cancer, that were described in this paper.<br><strong>Conclusions</strong>: Effective pain relief presents a positive effect, both on the physical and mental state of the patient. It also helps to maintain calm mental health among relatives. Nowadays, integration of the best methods for pain relief that are characterized as humanitarian, easily accessible and effective, seems to be one of the biggest challenges for both oncological and palliative health workers.</p> Izabela Marzec , Kinga Grabska , Marta M. Fudalej , Anna M. Badowska-Kozakiewicz Copyright (c) 2021 Medical Education http://creativecommons.org/licenses/by-nc-nd/4.0/ https://www.journalsmededu.pl/index.php/OncoReview/article/view/1146 Sun, 10 Jan 2021 00:00:00 +0100